Advertisement

Topics

Arch Biopartners Provides Toxicology Update for Metablok

12:05 EDT 29 Oct 2018 | Investing News Network

Arch Biopartners (TSXV:ARCH;OTCQB:ACHFF) today provided an update on the general results from toxicology and pharmacology studies evaluating Metablok, the Company’s lead drug candidate for treating acute kidney injury. As quoted in the press release: In seven day studies involving rodents and another larger animal species, there were no significant drug-related side effects in the toxicology … Continued

The post Arch Biopartners Provides Toxicology Update for Metablok appeared first on Investing News Network.

Original Article: Arch Biopartners Provides Toxicology Update for Metablok

NEXT ARTICLE

More From BioPortfolio on "Arch Biopartners Provides Toxicology Update for Metablok"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...